GSK Puts Tail End Brands On The Block In India
GlaxoSmithKline is believed to be keen to divest close to a dozen tail-end brands across therapy groups including anti-infectives and dermatology in India as it tweaks its portfolio to focus on sustained profitable growth.
You may also be interested in...
Following its purchase of PaxVax earlier this month, Emergent is taking on Narcan nasal spray for opioid overdose as part of its acquisition of Adapt. Also-busy Evotec teams up with Centogene in rare genetic disease and Novo in diabetes/obesity.
GlaxoSmithKline has initiated portfolio rationalization measures in India as the British multinational reshapes its emerging markets business model with an eye on driving sustained profitable growth. But the company has also underscored its long-term commitment to the country, where it expects to build on its “strong heritage” and expand patient access.
The Organization of Pharmaceutical Producers of India (OPPI) essentially reflects the views of foreign firms in the country. In an interview with Scrip, OPPI’s new chief and GSK vice president (South Asia) and managing director (India) Annaswamy Vaidheesh shares the industry body’s take on several critical issues including the Indian government’s push for generic medicines and why the effective contract manufacturing model should not be “disrupted” by proposed policy reform.